Agios Reports Q3 2026 Revenue Surge Driven by Thalassemia Product Launch
Agios reported a significant increase in net revenue for the third quarter of 2026, reaching $55.4 million. This represents a fourfold increase compared to the same period last year, primarily driven by record product revenue from its thalassemia launch. US-based revenue grew 20% sequentially, while ex-US revenue saw a 74% increase due to early access programs in Europe following regulatory approvals. The company reported a net loss of $65 million, which is an improvement over the $103.4 million loss recorded in the prior year. To reach its target of non-GAAP profitability by 2028, Agios has implemented cost-saving measures, including a 35% reduction in R&D headcount. The company maintains a strong liquidity position with $907 million in cash and marketable securities.
Tickers: $AAPL $AGIO $AMZN $GOOG $META $MSFT $NVDA $TSLA
Topics: Cash Position Net Loss Net Revenue R&D Expense Thalassemia Launch
Read the full article at Motley Fool
Part of the story Agios Reports Q3 2026 Revenue Surge Driven by Thalassemia Product Launch (3 articles)